In validation cohort, the Wiot-LM group were further divided into Wiot-LM patients without brain metastases (Wiot-LM/BrM), and Wiot-LM patients with BrM (BrM) to analyze the influence of brain metastases on CSF HE4 and CEACAM6 level. The gene discussed is WFDC2; the disease is lymphangioma.